I
N
N
O
V
A
T
O
R
S
&
T
R
A
I
L
B
L
A
Z
E
R
S
President, Co-Founder &
ChieF oPerating oFFiCer
AntoXA CorporAtion
Ashley Meyers
For the interview, see page 42
How is your organization cHanging
tHe game witHin your industry
sector?
AntoXa is producing high-value therapeutic pro-
tein drugs to protect against chemical and bio-
logical threats using a plant-based manufacturing
platform, vivoXPRESS®. Our pipeline includes
antidotes to ricin poisoning and nerve agent ex-
We believe we have a
best-in-class drug, and
we are excited by the
support and recognition
we are seeing from new
potential customers in
government, defence
and public health.
posure as well as a nerve regeneration therapy
for trauma injuries. Typically drug products like
these are manufactured in mammalian cells,
which makes them expensive; our products can
be made for 10 per cent of the traditional cost.
Our platform is also uniquely positioned to rapid-
ly respond to emerging threats and can be easily
scaled – you simply grow more plants (i.e. verti-
cal farming).
wHat is tHe one tHing
tHat Has you most
fired up today?
